Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4

NEXT STORY
CloudMD Graduates to the OTCQX; Begins Trading Today Under “DOCRF”
PREV STORY
Merus Presents Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

XpresSpa Group™ Receives Approval for a $2 Million Program with the Centers for Disease Control and Prevention (CDC) for Biosurveillance Tracking in Collaboration with Concentric by Ginkgo at Three Major U.S. Airports

author_avatar
NASDAQ Market News

Chembio Diagnostic Systems Prevails in International Arbitration Against BioSure (UK) Ltd

author_avatar
NASDAQ Market News

Genocea Reports Second Quarter 2018 Financial and Operating Results

Neoantigen vaccine program GEN-009 Phase 1/2a clinical trial underway ATLAS™ platform continues to stand ...

author_avatar
NASDAQ Market News